Company RAMM Pharma Corp.

Equities

RAMM

CA75150G1046

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 11:12:06 16/05/2024 pm IST			5-day change	1st Jan Change
0.04 ^CAD	0.00%		0.00%	-27.27%

29/03	RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
19/03	RAMM Pharma Corp. cancelled the transaction announced on September 5, 2023	CI

RAMM Pharma Corp. is a Canada-based company that is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp-based products with a diversified international production and sales platform. The Company operates a pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant-derived cannabinoid pharmaceutical products that have been authorized for sale and/or use in several Latin American countries. The Company has a pipeline of products, including registered hemp-based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at its formulation facility in Montevideo, Uruguay. The Company's brands include NettaPet and NettaVet. Its subsidiaries include Canapar Corp., HemPoland S.p. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

CAD in Million	2022	Weight	2023	Weight	Delta
Medical Devices and Consumables 42.1 %	2	46.8 %	2	42.1 %	+16.99%
Pharmaceutical Formulations 40.8 %	2	42.0 %	2	40.8 %	+26.45%
Services 13.4 %	0	4.6 %	1	13.4 %	+277.94%
Cosmetics 3.6 %	0	4.2 %	0	3.6 %	+13.06%

CAD in Million	2022	Weight	2023	Weight	Delta
Uruguay 68.8 %	4	91.8 %	3	68.8 %	-2.69%
Poland 29.2 %	0	7.6 %	1	29.2 %	+398.89%
Italy 2.1 %	0	0.6 %	0	2.1 %	+377.66%

Managers	Title	Age	Since
Jackie Burnett CEO	Chief Executive Officer	-	01/19/01
José Roldan DFI	Director of Finance/CFO	-	09/22/09
Edelma Ros CTO	Chief Tech/Sci/R&D Officer	-	-
Leticia Cuñetti CTO	Chief Tech/Sci/R&D Officer	-	-
Guillermo Delmonte COO	Chief Operating Officer	-	01/19/01

Members of the board	Title	Age	Since
Eric Klein BRD	Director/Board Member	64	01/19/01
Daniel Augereau BRD	Director/Board Member	80	01/19/01
Jackie Burnett CEO	Chief Executive Officer	-	01/19/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	119,389,317	88,014,317 ( 73.72 %)	0	73.72 %

Name	Equities	%	Valuation
Jackie Burnett 17.23 %	20,575,000	17.23 %	1 M $
Daniel Augereau 9.046 %	10,800,000	9.046 %	648 000 $

RAMM Pharma Corp.

Scotia Plaza 40 King Street West

M5H 3C2, Toronto

http://www.wearerammpharma.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
RAMM PHARMA CORP.	-27.27%	35.1L
IQVIA HOLDINGS INC.	-0.09%	4.21TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.92TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.6TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.89TCr
BIO-TECHNE CORPORATION	+8.61%	1.32TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.22TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	1.14TCr

Other Biotechnology & Medical Research